Pfizer Inc. (NYSE:PFE) Shares Sold by Gleason Group Inc.

Gleason Group Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 34.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,520 shares of the biopharmaceutical company’s stock after selling 793 shares during the quarter. Gleason Group Inc.’s holdings in Pfizer were worth $44,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Worth Asset Management LLC acquired a new stake in Pfizer during the first quarter worth about $29,000. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer during the third quarter valued at about $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in shares of Pfizer during the third quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC increased its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. UBS Group dropped their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Friday, March 1st. Truist Financial lowered their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE traded down $0.03 during trading on Friday, hitting $27.75. 40,466,657 shares of the company were exchanged, compared to its average volume of 47,662,984. The stock has a market capitalization of $157.14 billion, a P/E ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $42.22. The firm’s 50 day moving average price is $27.45 and its 200-day moving average price is $29.45.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.14 EPS. On average, research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.